pyrrolidone hydrotribromide | 52215-12-0

• 英文名称: pyrrolidone hydrotribromide
• 英文别名: PHT；2-pyrrolidone hydrotribromide；pyrrolidinone hydrotribromide
• CAS: 52215-12-0
• 化学式: Br₃H*C₄H₇NO
• 分子量: 325.826
• InChiKey: GZGCJWMZGQDMLC-UHFFFAOYSA-N

物化性质

• 熔点：
  88-90 °C(lit.)
• 密度：
  1.9879 (rough estimate)
• 溶解度：
  sol THF, dioxane, DMSO.

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38

反应信息

• 作为反应物：
  描述：

  1-[7-氨基-5-(2-溴丙基)-2,3-二氢-1H-吲哚-1-基]-乙酮 、 pyrrolidone hydrotribromide 在 硫酸 作用下， 以 四氢呋喃 为溶剂， 生成 1-acetyl-5-(2-bromopropionyl)indoline
  参考文献：
  名称：

  1,5,7-trisubstituted indoline compounds and salts thereof

  摘要：

  Indoline化合物由以下公式代表：##STR1## 其中R代表饱和或不饱和的脂肪族酰基，可能具有一个或多个卤素原子、一个羟基、一个较低的烷氧基、一个羧基、一个较低的烷氧羰基、一个环烷基或一个芳基作为取代基；一个羟基烷基基团；一个脂肪族酰氧烷基基团；一个具有较低烷氧基、一个羧基、一个较低烷氧羰基、一个芳基取代的较低烷氧羰基、一个氨基群、一个单烷基或二烷基取代的氨基群或一个氰基作为取代基的较低烷基基团；一种芳香族酰基，可能具有一个或多个卤素原子作为取代基；一种呋喃酰基或吡啶羰基；R.sup.1代表一种较低烷基基团，可能具有一个或多个卤素原子或一个芳基作为取代基；及其药学上可接受的盐，表现出对尿道收缩的选择性抑制作用，因此可用作治疗排尿困难的治疗剂，包括较少引起低血压，包括姿势性低血压。

  公开号：

  US05387603A1
• 作为试剂：
  描述：

  4-甲基环己酮 在 pyrrolidone hydrotribromide 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 2-溴-4-甲基环己酮
  参考文献：
  名称：

  Synthesis and Biological Activity of (Hydroxymethyl)- and (Diethylaminomethyl)benzopsoralens

  摘要：

  Some benzopsoralens, carrying a hydroxymethyl or a diethylaminomethyl group at the 3, 5, 8, and 11 positions, were prepared, and their biological activity was compared with that of 4-(hydroxymethyl)benzopsoralen (BP). 5-(Hydroxymethyl)benzopsoralen (7b), 11-(hydroxymethyl)benzopsoralen (7c), and 11-(diethylaminomethyl)benzopsoralen (8c) induced marked antiproliferative effects in mammalian cells by simple incubation in the dark; this activity appeared to be related to their ability to inhibit topoisomerase II. Benzopsoralens appeared to be more active, especially BP and 7c, upon WA activation. Compounds carrying a methyl group at the 4 position together with a hydroxymethyl Or diethylaminomethyl at the 8 position (7d and 8d, respectively) were also effective, although to a lower extent; instead, a substituent at the 3 position canceled all activity. Benzopsoralens did not induce interstrand cross-links in DNA in vitro, as seen in the induction of cytoplasmic <> mutations and double-strand breaks in yeast. This behavior is also compatible with their low mutagenic activity in E. coli WP2 and with the absence of any phototoxicity on the skin. For these features, benzopsoralens seem to be interesting potential drugs for PUVA photochemotherapy and photopheresis. The activity shown in the dark is not sufficient for their possible use as antitumor drugs, but it does offer a new model for the study of topoisomerase inhibitors.

  DOI：

  10.1021/jm991028s

文献信息

• Propenone derivatives
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：US05952355A1

  公开（公告）日：1999-09-14

  The present invention relates to propenone derivatives represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, or YR.sup.5 (wherein Y represents S or O; and R.sup.5 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a substituted or unsubstituted cyclic ether residue); R.sup.2 and R.sup.3 independently represent hydrogen, lower alkyl, or substituted or unsubstituted aralkyl, or alternatively R.sup.2 and R.sup.3 are combined to form substituted or unsubstituted methylene or ethylene; R.sup.4 represents hydrogen, hydroxy, lower alkyl, substituted or unsubstituted aralkyl, lower alkoxy, substituted or unsubstituted aralkyloxy, or halogen; and X represents substituted or unsubstituted indolyl; or pharmaceutically acceptable salts thereof.

  本发明涉及以下式(I)所代表的丙酮衍生物：##STR1##其中R.sup.1代表氢、取代或未取代的较低烷基、取代或未取代的芳基，或YR.sup.5（其中Y代表S或O；R.sup.5代表取代或未取代的较低烷基、取代或未取代的芳基、取代或未取代的杂芳基，或取代或未取代的环氧基残基）；R.sup.2和R.sup.3独立地代表氢、较低烷基，或取代或未取代的芳基烷基，或者R.sup.2和R.sup.3结合形成取代或未取代的亚甲基或乙烯基；R.sup.4代表氢、羟基、较低烷基、取代或未取代的芳基烷基、较低烷氧基、取代或未取代的芳基烷氧基，或卤素；X代表取代或未取代的吲哚基；或其药学上可接受的盐。
• N,N'-bis[3-substituted-4-hydroxypheyl)-2-hydroxyethyl)]
  申请人：SmithKline Corporation

  公开号：US03933913A1

  公开（公告）日：1976-01-20

  N,N'-Bis[2-(3-substituted-4-hydroxyphenyl)-ethyl or-2-hydroxyethyl]-polymethylenediamines having .beta.-adrenergic stimulant activity particularly as selective bronchodilators, are prepared generally by condensation of an N-benzylphenethylamine with a polymethylene dihalide or by reaction of an .alpha.-bromoacetophenone with an N,N'-dibenzyl-polymethylenediamine, with further operations depending on the nature of the 3-substituent, and subsequently hydrogenating catalytically with for example palladium-on-carbon. The key intermediates are also part of the invention.

  N,N'-双[2-(3-取代-4-羟基苯基)-乙基或-2-羟基乙基]-聚甲基二胺具有β-肾上腺素刺激活性，特别作为选择性支气管扩张剂。通常通过N-苄基苯乙胺与聚甲烯二卤化物的缩合或α-溴代苯乙酮与N,N'-双苄基-聚甲基二胺的反应制备，随后根据3-取代基的性质进行进一步操作，最后进行例如钯-碳上的催化氢化。关键中间体也是该发明的一部分。
• Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
  申请人：Abbott Laboratories

  公开号：US06472416B1

  公开（公告）日：2002-10-29

  The present invention encompasses novel sulfonylphenylpyrazole compounds useful in the treatment of cyclooxygenase-2 mediated diseases.

  本发明涵盖了新型磺酰基苯基吡唑化合物，可用于治疗环氧化酶-2介导的疾病。
• .alpha.-Aminoalkyl-4-hydroxy-3-alkylsulfonylmethylbenzyl alcohols having
  申请人：SmithKline Corporation

  公开号：US03961076A1

  公开（公告）日：1976-06-01

  .alpha.-Aminoalkyl-4-hydroxy-3-alkylsulfonylmethylbenzyl alcohols having .beta.-adrenergic stimulant activity, particularly as selected bronchodilators, are prepared from 4-hydroxyphenones by conversion to a 3-alkylsulfonylmethylphenone, bromination of these phenones and treatment of the resulting .alpha.-bromo derivatives with an N-benzyl secondary amine, followed by catalytic hydrogenation to remove the benzyl groups and reduce the ketone moiety.

  具有β-肾上腺素激动剂活性的.alpha.-氨基烷基-4-羟基-3-烷基磺酰甲基苯甲醇，特别是作为选择的支气管扩张剂，是通过将4-羟基苯酮转化为3-烷基磺酰甲基苯酮，溴化这些苯酮，并处理得到的.alpha.-溴衍生物与N-苄基二级胺，随后进行催化氢化以去除苄基基团并减少酮基团而制备的。
• 4-Hydroxy-.alpha.-[(3,4-methylenedioxyphenyl)isopropylaminoethyl]-3-(meth
  申请人：SmithKline Corporation

  公开号：US03966770A1

  公开（公告）日：1976-06-29

  4-Hydroxy-.alpha.-[(3,4-methylenedioxyphenyl)isopropylaminomethyl]-3-(methy lsulfonylmethyl)benzyl alcohol having .beta.-adrenergic stimulant activity, particularly as a selective bronchodilator, is prepared from 4-hydroxyacetophenone by conversion to 3-methylsulfonylmethylacetophenone, bromination and conversion of this phenone to the phenylglyoxal and treatment of the resulting glyoxal derivative with 3,4-methylenedioxyphenylisopropylamine followed by simultaneous reduction of the imine and ketone moieties and catalytic hydrogenation to remove the benzyl group.

  4-羟基-.alpha.-[(3,4-亚甲二氧基苯基)异丙胺甲基]-3-(甲磺基甲基)苯甲醇具有β-肾上腺素激动活性，特别是作为选择性支气管扩张剂，是通过将4-羟基苯乙酮转化为3-甲基磺酰基甲基苯乙酮，溴化和将该酮转化为苯甘醛，然后用3,4-亚甲二氧基苯基异丙胺处理所得的甘醛衍生物，随后同时还原亚胺和酮基团，并进行催化氢化以去除苄基而制备的。